IDC Recommends Open Offer for Rekvina Laboratories Ltd as Fair and Reasonable
The Committee of Independent Directors (IDC) of Rekvina Laboratories Limited has concluded its review of the open offer made by three acquirers, deeming the offer price fair and reasonable. The recommendation was made following the meeting held on June 24, 2026, concerning the acquisition of a portion of the company's equity shares.The IDC members unanimously approved their recommendations regarding the Open Offer. The offer involves Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel (collectively the Acquirers), who intend to acquire up to 28,90,100 Equity Shares of Rekvina Laboratories Limited.
The committee stated that the Offer Price of ₹10 per Equity Share is fair and reasonable in accordance with relevant regulations. This assessment was made after perusing various documents, including a Public Announcement dated March 16, 2026, a Detailed Public Statement published on March 24, 2026, and the Letter of Offer dated June 20, 2026.
The strategic rationale for the acquisition involves expanding Rekvina Laboratories Limited's operations within the existing line of business through the integration of Radiant Parenterals Limited’s products, services, and operations. The management noted that this consolidation aims to increase market share, strengthen the company's position in the industry segment, leverage operational efficiencies through shared resources, and achieve long-term shareholder value.
The IDC members also highlighted for public shareholders the closing market price of Rekvina Laboratories Limited’s Equity Shares on the BSE Limited as of June 23, 2026, which stood at ₹37.45 per share.
A summary of the offer and related details are presented below:
| Metric | Details |
|---|---|
| Target Company | Rekvina Laboratories Limited |
| Acquirers | Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel |
| Total Shares Offered (Maximum) | 28,90,100 Equity Shares (representing 26% of Expanded Share Capital) |
| Offer Price per Share | ₹10/- |
| Total Consideration | ₹2,89,01,000/ - |
| Manager to the Offer | Vivro Financial Services Private Limited |
The IDC members confirmed that none of them hold any Equity Shares in the Target Company, nor do they have any contracts or relationships with the company. They also stated that no member of the IDC had traded in the equity shares of Rekvina Laboratories Limited during the twelve months preceding the date of the announcement.
Public shareholders are advised to independently evaluate the Open Offer and the market performance of the Target Company’s scrip when making a decision regarding tendering their shares.
The recommendations will be published in various newspapers, including Financial Express (English/Regional), Jansatta (Hindi), and Navshakti (Marathi).
Stock Price Movement
At 10:14 AM, Rekvina Laboratories Ltd shares are dipping, currently priced at ₹35.98, reflecting a 1.99% decline. The stock is trading completely flat, as the intraday high and low are locked steady at the ₹35.98 price point.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.